Press Releases

Press Releases

Date Title & Summary Additional Formats
10/04/18
Cidara Therapeutics Presents Results from Successful Phase 2 STRIVE Trial Evaluating Rezafungin at IDWeek 2018
STRIVE clinical trial successfully met all primary endpoints demonstrating the efficacy and safety of rezafungin for the treatment of invasive fungal infections Rezafungin data featured in one oral and three poster presentations showcase broad clinical utility of Cidara’s novel once-weekly
09/27/18
Cidara Therapeutics Initiates Phase 3 Trial of Lead Antifungal Rezafungin for Treatment of Invasive Candida Infections
SAN DIEGO --(BUSINESS WIRE)--Sep. 27, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and
09/25/18
FDA Grants QIDP and Fast Track Designations to Cidara Therapeutics’ Rezafungin Prophylaxis Development Program
Rezafungin designated for the prevention of invasive fungal infections in adults undergoing bone marrow transplantation SAN DIEGO --(BUSINESS WIRE)--Sep. 25, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today
09/24/18
Cidara Therapeutics to Present at Two Upcoming Investor Conferences
SAN DIEGO , Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein , Ph.D., president and chief executive officer of Cidara, is scheduled to present at two
09/12/18
Cidara Therapeutics Appoints David Gollaher, Ph.D., to Board of Directors
Former Head of Global Government Affairs and Policy at Gilead Sciences led wide-ranging collaborations with leading academic institutions and non-profit groups SAN DIEGO --(BUSINESS WIRE)--Sep. 12, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel
09/12/18
Cidara Therapeutics to Present Data on Lead Antifungal Rezafungin at IDWeek 2018
Presentations will highlight data demonstrating the broad clinical utility, safety and potency of rezafungin to fight invasive fungal infections SAN DIEGO --(BUSINESS WIRE)--Sep. 12, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including
09/04/18
Cidara Therapeutics to Present New Cloudbreak Data at the ESCMID/ASM Conference and 16th Annual Discovery on Target Meeting
Data highlight potential of Cloudbreak immunotherapy candidates for the treatment of multi-drug resistant Gram-negative bacterial infections SAN DIEGO --(BUSINESS WIRE)--Sep. 4, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including
08/08/18
Cidara Provides Corporate Update and Reports Second Quarter 2018 Financial Results
SAN DIEGO , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended June 30, 2018 and provided an update on its corporate activities
06/15/18
Cidara Therapeutics Announces Oral Presentations on Rezafungin at Two Upcoming Global Conferences
Data Will Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections SAN DIEGO --(BUSINESS WIRE)--Jun. 15, 2018-- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today
05/23/18
Data to be Presented at ASM Microbe 2018 Demonstrate the Efficacy and Safety of Cidara’s Rezafungin for the Treatment of Invasive Fungal Infections
Four accepted presentations include a late-breaker featuring Phase 2 STRIVE trial data and three posters describing the activity of rezafungin against fungal pathogens SAN DIEGO --(BUSINESS WIRE)--May 23, 2018-- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel